Marksans Pharma

71
Buy
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE750C01026
  • NSEID: MARKSANS
  • BSEID: 524404
INR
273.80
4.75 (1.77%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 10.75 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Operating Income
2,950.00
2,622.00
2,177.00
1,852.00
1,490.00
1,376.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
2,950.00
2,622.00
2,177.00
1,852.00
1,490.00
1,376.00
Expenditure (Ex Depriciation)
Stock Adjustments
-136.00
-183.00
-73.00
-6.00
12.00
-136.00
Raw Materials Consumed
1,413.00
1,327.00
1,111.00
927.00
703.00
731.00
Power & Fuel Cost
54.00
40.00
36.00
24.00
18.00
16.00
Employee Cost
420.00
350.00
293.00
239.00
220.00
197.00
Operating Expenses
155.00
140.00
87.00
18.00
12.00
34.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
260.00
256.00
127.00
102.00
119.00
109.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
71.00
41.00
26.00
164.00
115.00
39.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
2,350.00
2,090.00
1,718.00
1,512.00
1,231.00
1,036.00
Operating Profit (PBDIT) excl Other Income
600.00
532.00
458.00
339.00
258.00
339.00
Other Income
82.00
66.00
50.00
59.00
41.00
6.00
Operating Profit (PBDIT)
683.00
599.00
508.00
398.00
300.00
346.00
Interest
24.00
11.00
11.00
9.00
8.00
7.00
Profit before Depriciation and Tax
659.00
587.00
497.00
389.00
292.00
338.00
Depreciation
98.00
83.00
74.00
51.00
44.00
36.00
Profit Before Taxation & Exceptional Items
560.00
503.00
423.00
337.00
247.00
302.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
560.00
503.00
423.00
337.00
247.00
302.00
Provision for Tax
140.00
121.00
108.00
72.00
60.00
63.00
Profit After Tax
420.00
382.00
314.00
265.00
186.00
238.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
1,422.00
1,068.00
777.00
509.00
334.00
85.00
Profit Available for appropriations
1,839.00
1,449.00
1,091.00
775.00
519.00
321.00
Appropriations
1,839.00
1,449.00
1,091.00
775.00
519.00
321.00
Equity Dividend (%)
90.00%
80.00%
60.00%
50.00%
25.00%
25.00%
Earnings Per Share
9.22
8.40
6.92
6.41
4.51
5.76
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 12.51% vs 20.46% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 12.78% vs 16.16% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is 106.90% vs 4.08% in Mar 2025

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2026 is 9.79% vs 21.51% in Mar 2025

Compare Profit and Loss Results of Marksans Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,950.00
1,196.00
1,754.00
146.66%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,950.00
1,196.00
1,754.00
146.66%
Expenditure (Ex Depriciation)
Stock Adjustments
-136.00
-23.00
-113.00
-491.30%
Raw Materials Consumed
1,413.00
260.00
1,153.00
443.46%
Power & Fuel Cost
54.00
6.00
48.00
800.00%
Employee Cost
420.00
346.00
74.00
21.39%
Operating Expenses
155.00
6.00
149.00
2,483.33%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
260.00
111.00
149.00
134.23%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
71.00
59.00
12.00
20.34%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,350.00
956.00
1,394.00
145.82%
Operating Profit (PBDIT) excl Other Income
600.00
239.00
361.00
151.05%
Other Income
82.00
5.00
77.00
1,540.00%
Operating Profit (PBDIT)
683.00
245.00
438.00
178.78%
Interest
24.00
10.00
14.00
140.00%
Profit before Depriciation and Tax
659.00
235.00
424.00
180.43%
Depreciation
98.00
37.00
61.00
164.86%
Profit Before Taxation & Exceptional Items
560.00
198.00
362.00
182.83%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
560.00
198.00
362.00
182.83%
Provision for Tax
140.00
49.00
91.00
185.71%
Profit After Tax
420.00
149.00
271.00
181.88%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
1,422.00
377.00
1,045.00
277.19%
Profit Available for appropriations
1,839.00
527.00
1,312.00
248.96%
Appropriations
1,839.00
527.00
1,312.00
248.96%
Equity Dividend (%)
90%
73.1%
16.90
Earnings Per Share
9.22
24.43
-15.21
-62.26%
Profit And Loss - Net Sales
Net Sales 2,950.94 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 12.51% vs 20.46% in Mar 2025

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 600.78 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 12.78% vs 16.16% in Mar 2025

Profit And Loss - Interest
Interest 24.12 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 106.90% vs 4.08% in Mar 2025

Profit And Loss - Profit After Tax
Profit After Tax 420.06 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 9.79% vs 21.51% in Mar 2025